Treatment of Exogenous Cushing's Syndrome

Introduction to Management

• The European Respiratory Society suggests avoiding concomitant azole antifungals (itraconazole, voriconazole) with inhaled budesonide or fluticasone, as this combination significantly increases the risk of exogenous Cushing's syndrome 1
• The European Respiratory Society also recommends avoiding methylprednisolone when combined with oral itraconazole due to a higher risk of exogenous Cushing's syndrome and subsequent adrenal insufficiency 1

Monitoring and Management

• The Lancet Diabetes and Endocrinology guidelines recommend monitoring for clinical features of adrenal insufficiency, including fatigue, weakness, nausea, hypotension, and hypoglycemia during the tapering process 2
• According to The Lancet Diabetes and Endocrinology, mifepristone (a glucocorticoid receptor blocker) can be considered for severe cases of hypercortisolism, though it requires careful monitoring as cortisol levels remain elevated and only clinical features can assess treatment response 2

Pharmacologic Interventions

• The American Heart Association, as published in Hypertension, suggests using spironolactone or eplerenone for hypertension, as these block mineralocorticoid receptor activation from excess cortisol 3
• The Lancet Diabetes and Endocrinology recommends appropriate glucose-lowering therapy for hyperglycemia, with consideration of GLP-1 receptor agonists or DPP-4 inhibitors if pasireotide is used 2

Treatment for Exogenous Steroid-Induced Cushing's Syndrome

Special Considerations

• The European Respiratory Journal recommends considering switching to lower-dose inhaled steroids or alternative medications for underlying condition, using spacer devices with inhaled steroids to reduce systemic absorption, and rinsing mouth after inhaled steroid use to decrease swallowed portion 4

Monitoring During Treatment

• The Lancet Diabetes and Endocrinology suggests monitoring for resolution of Cushing's features, including weight, blood pressure, glucose levels, and physical stigmata, and considering medications that block cortisol synthesis or action for severe cases with complications 5

Adjunctive Treatments

• The Lancet Diabetes and Endocrinology recommends considering medications that block cortisol synthesis (ketoconazole, metyrapone) or action (mifepristone) for severe cases with complications 5

Treatment Strategy for Exogenous Cushing's Syndrome

Initial Management: Discontinuation and Tapering

• The primary treatment for exogenous Cushing's syndrome is immediate discontinuation of the causative glucocorticoid if medically feasible, followed by gradual tapering to prevent adrenal insufficiency, as recommended by The Endocrine Society 6
• Stop the exogenous glucocorticoid source immediately if possible, including oral glucocorticoids, injectable steroids, inhaled corticosteroids, and topical glucocorticoid preparations, according to The Endocrine Society 6

Treatment of Exogenous Cushing Syndrome

Initial Management and Diagnosis

• The Endocrine Society recommends identifying and stopping all sources of exogenous glucocorticoids, followed by gradual tapering to prevent adrenal insufficiency, in patients with exogenous Cushing syndrome 7

Management of Complications

• The American Heart Association suggests using mineralocorticoid receptor antagonists, such as spironolactone or eplerenone, as first-line therapy for hypertension in patients with exogenous Cushing syndrome, as they block the mineralocorticoid effects of excess cortisol on renal sodium absorption 8
• The use of cortisol synthesis inhibitors, such as ketoconazole or metyrapone, may be considered in severe cases of exogenous Cushing syndrome with complications, although they are typically reserved for endogenous Cushing syndrome 8

Common Pitfalls to Avoid

• The Endocrine Society advises against assuming all Cushing syndrome is exogenous, and recommends ruling out endogenous causes before attributing symptoms solely to medication 7

Management of Exogenous Cushing Syndrome

Treatment and Management

• The American Heart Association recommends using mineralocorticoid receptor antagonists, such as spironolactone 25-50 mg daily or eplerenone 50-100 mg daily, as first-line therapy for hypertension in patients with exogenous Cushing syndrome, as they directly counteract cortisol's mechanism of causing hypertension 9
• The European League Against Rheumatism suggests initiating glucose-lowering therapy with metformin as first-line, or considering GLP-1 receptor agonists or DPP-4 inhibitors, and monitoring blood glucose closely during taper as insulin requirements will decrease 10
• The American College of Rheumatology recommends prescribing calcium 1000-1500 mg daily and vitamin D 800-1000 IU daily immediately for patients who received prednisone >7.5 mg daily for >3 months, and initiating bisphosphonate therapy based on risk factors including low BMD, female gender, postmenopausal status, older age, and low body mass index 10
• The American Gastroenterological Association suggests prescribing proton pump inhibitors, such as omeprazole 20 mg daily or equivalent, or misoprostol, or switching to COX-2 selective inhibitor, for patients on concomitant NSAIDs 10
• The Infectious Diseases Society of America recommends monitoring for opportunistic infections during taper, as immunosuppression persists, and avoiding live vaccines until HPA axis recovery is confirmed 10
• The Endocrine Society suggests assessing body weight to track resolution of central obesity, blood pressure at each visit, fasting glucose or HbA1c every 4-8 weeks, and serum potassium if on mineralocorticoid antagonists, at each dose reduction (every 2-4 weeks) 10
• The American Association for the Study of Liver Diseases recommends measuring morning cortisol level once daily dose reaches physiologic range (≤5 mg prednisone) to assess HPA axis recovery, and continuing stress-dose coverage until recovery is confirmed, which may take up to 12 months after prolonged high-dose therapy 11